Kestrel Therapeutics Doses First Patient in KRAS Trial
WATERTOWN, MASSACHUSETTS, April 28, 2026 Kestrel Therapeutics Inc. has announced a major clinical milestone with the first patient dosed...
solid tumors
Advertisement
Repertoire Immune Medicines Doses First Patient in Phase 1/2 Trial
Cambridge, Massachusetts, USA – April 23, 2026 Repertoire Immune Medicines announced a major clinical milestone with the first participant...
Enara Bio Showcases ENA101 Cancer Immunotherapy at AACR
OXFORD, UK, April 20, 2026 Enara Bio announced the presentation of breakthrough preclinical data for ENA101, its first-in-class bispecific...
Verismo SynKIR-110 Shows Phase 1 Safety in Solid Tumors
PHILADELPHIA, April 20, 2026 Verismo Therapeutics has reported promising initial Phase 1 clinical data from its STAR-101 trial, evaluating...
Oricell Therapeutics Secures $110M for CAR-T Expansion
SHANGHAI, China, April 10, 2026 Oricell Therapeutics Holdings Limited has successfully closed a $110 million pre-IPO financing round, marking...
Advertisements
IDEAYA Biosciences Doses First Patient in IDE574 Trial
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
Blood Test Tracks Immunotherapy Response in Solid Tumors
FOSTER CITY, Calif., March 3, 2026 Adela, Inc. has announced the publication of new clinical validation data in npj...
FDA Clears IND for CS2009 Trispecific Antibody Trial
SUZHOU, China, Feb. 15, 2026 — CStone Pharmaceuticals announced that the U.S. Food and Drug Administration has granted Investigational...
FDA Clears PRD-101 Nano Cancer Drug for Phase 1
SEONGNAM, South Korea, Feb. 6, 2026 — PharmaResearch Co., Ltd. announced that the U.S. Food and Drug Administration (FDA)...
Janux and BMS Partner on Tumor-Activated Cancer Therapy
SAN DIEGO, January 22, 2026 — Janux Therapeutics announced a collaboration and exclusive worldwide license agreement with Bristol Myers...
Advertisement
